Emotional manifestations of PD: Neurobiological basis

CASTRIOTO, Anna, et al.


DOI : 10.1002/mds.26587
PMID : 27041545
Emotional Manifestations of PD: Neurobiological Basis

Anna Castrioto, MD, PhD,1,2,3 Stéphane Thobois, MD, PhD,4,5 Sebastien Carnicella, PhD,1,2 Audrey Maillet, PhD,4 and Paul Krack, MD, PhD1,2,3*

1Univ. Grenoble Alpes, Grenoble Institut des Neurosciences, GIN, Grenoble, France
2Inserm, U1216, Grenoble, France
3Movement Disorders Unit, Neurology Department, CHU de Grenoble, Grenoble, France
4CNRS, UMR 5229, Centre de Neurosciences Cognitives, Bron, France
5Hospices Civils de Lyon, Hôpital Neurologique, Neurologie C; Université Lyon I, Faculté de Médecine et de Médecine Lyon Sud Charles Mérieux, Lyon, France

ABSTRACT: Neuropsychiatric symptoms are common and disabling in PD. Their neurobiological bases are complex, partly because of the disease itself and partly because of the dopaminergic treatment. The aim of this review is to focus on the emotional manifestations stemming from the neurodegenerative process itself. We focus on depression, anxiety, apathy, and fatigue, which can all be part of the clinical spectrum of premotor disease and may be improved or masked by medications targeting parkinsonian motor signs or psychiatric symptoms as the disease progresses. Findings from clinical, neuroimaging, and animal studies are reviewed, showing a major contribution of the dopaminergic system to the pathophysiology of these disabling symptoms. Degeneration of noradrenergic and serotonergic projection systems also has an impact on psychiatric symptoms of PD. The available literature is reviewed, but at present there is a lack of studies that would allow disentangling the separate contribution of each of the monoaminergic systems. The use of a pragmatic classification of all these symptoms under the umbrella of hypodopaminergic behavioral syndrome seems clinically useful, as it emphasizes the crucial, although not exclusive, nature of their dopaminergic neurobiological basis, which has important implications in the clinical management of PD. © 2016 International Parkinson and Movement Disorder Society

Key Words: Parkinson’s disease; dopamine; apathy; depression; anxiety

Psychiatric symptoms are so common in Parkinson’s disease (PD) that it has been defined as a neuropsychiatric disorder.1 Neuropsychiatric symptoms, that is, emotional and cognitive symptoms, constitute a major source of disability and can be socially disruptive.2-4 Some of these symptoms are a side effect of dopaminergic treatment (behavioral and dopaminergic replacement treatment addiction, nocturnal hyperactivity, hypomania, and punding).3-5 Others, like apathy, depression, and anxiety, seem more related to the disease itself, already presenting in the early stages of the disease and potentially preceding the first motor symptoms. As such, apathy, depression, and anxiety might at least in part be associated with insufficient dopaminergic drive.4-8 Fluctuating patients might experience apathy, depression, and anxiety in the off-periods, with euphoria, well-being, self-confidence, and hypomania characterizing the on-drug condition.9 The management of neuropsychiatric symptoms remains a challenge, also because it is not always easy to weight the relative contribution of medications, disease, and emotional response. The neurobiological bases of these symptoms are complex and not yet fully understood. The relative contribution of dopaminergic deficit and of other nondopaminergic systems is still under investigation. The objective of this review is to focus on the neuropsychiatric symptoms, which are most likely related to the disease itself, and to analyze...
the literature relating to their underlying mechanisms. We will therefore largely leave aside symptoms secondary to dopaminergic replacement treatment except when discussing neurodegeneration as part of the risk factors for developing iatrogenic behavioral complications. From a clinical point of view, patients with drug-naive de novo PD represent an interesting model that allows the investigation of symptoms related to the disease itself. Yet there are only a few studies on drug-naive de novo PD, and they carry the risk of including patients who will eventually develop an atypical parkinsonian syndrome. We will also report evidence based on human imaging studies and on animal models, which contribute to a better understanding of the mechanisms of the neurobiological basis of emotional manifestations in PD, as surrogates to the still-too-rare neuropathological-clinical correlation studies.10

Depression and Anxiety

Clinical Findings

Depression and anxiety are not only pervasive symptoms of PD,11,12 but they may also precede the onset of motor symptoms by several years.12-22 In a recent large epidemiological case-control study, depression and anxiety were found to be more frequent in PD patients up to 5 years before motor onset.17 A previous case-control study suggested that anxiety could be more strongly associated with PD and could precede motor onset by as much as 20 years.14 A recent study assessing populations at risk for PD, such as LRRK2 G2019S mutation carriers, supported this strong association, finding higher trait anxiety in G2019S carriers than in noncarriers.22 The risk of developing PD was found to be greater in a population with anxiety and correlated with severity of anxiety.23 Another recent case-control study, involving untreated PD patients, showed that of the nonmotor symptoms, depressed mood was already more frequent than anxiety 2 and even 10 years before motor onset.21 Once motor symptoms develop, both anxiety and depression remain more frequent in PD patients than in controls.18,19

It has been shown that in PD, anxiety and depression can either coexist or be present independently, suggesting that they are separate entities.11,24 In addition to actual depression and anxiety, patients may also experience acute mood fluctuations, with feelings of depression and anxiety as medication wears off.9,25,26 This suggests that the role of the dopaminergic system is critical. Besides generalized anxiety and anxiety related to fluctuations, specific phobias, panic disorder, and social phobia have been reported to be more frequent in PD than in the general population.12,27 Disease severity and fluctuations have been found to be risk factors for anxiety disorders.12,27

From a neuropathological point of view, besides dopaminergic denervation, the involvement of the locus coeruleus and the raphe nuclei (ie, the noradrenergic and serotonergic system, respectively) from the early stages of Braak’s classification can explain why depression and anxiety are frequent early nonmotor signs.10,28

Recognizing and treating depression and anxiety is important, as they have a negative impact on functioning.29,30 To optimize their management, it is important to distinguish between 2 phenomena, chronic depression and/or anxiety and psychotic fluctuations, because the neurobiology of the chronic psychiatric symptoms might be more complex than that of symptoms fluctuating with the sole dopaminergic treatment.

Only a few studies on management of depression and anxiety in de novo PD are available so far, suggesting a possible role of the dopaminergic system.18,31,32 Analysis of depression in the ADAGIO study32 suggested that rasagiline compared with placebo was associated with less depression, even after controlling for improvement of motor impairment. Studies in treated PD have shown that dopamine agonists improve mood, too,33-36 supporting the important role of the dopaminergic system in depression. Depressive symptoms in PD have been found to be associated with lower doses of dopamine agonists.16 Similarly, the MAO-B inhibitors rasagiline and selegiline have been shown to improve depression compared with placebo.37,38 Anxiety has also been found to respond to dopaminergic therapy.39 Moreover, depressed mood and anxiety experienced in the off-medication phase during nonmotor fluctuations are also improved by dopaminergic medication.25

Several controlled and uncontrolled studies have suggested that antidepressant treatment causes some improvement in depressed mood, although not consistently,40-48 pointing toward potential additional involvement of the serotonergic and/or noradrenergic systems. In a small open-label study, PD patients with depression were treated with pramipexole or sertraline.46 Depression improved in both groups, but the percentage of patients with full recovery was higher in the pramipexole group than in the sertraline group (60% vs 27%). When comparing selective serotonin uptake inhibitors with nonselective serotonin uptake inhibitors or a tricyclic antidepressants, the response to the latter seems to be faster, although their use is limited by their side effects.41-45,48 A placebo-controlled study on atomoxetine, a selective noradrenergic reuptake inhibitor, for depressed PD patients, showed a trend toward greater improvement with atomoxetine.49 All these findings highlight a possible role of the noradrenergic system in depression.50

Although there are no randomized, controlled studies about the effects of antidepressant drugs on anxiety,
studies on depression have shown that noradrenergic and serotonergic antidepressants also have a positive effect on anxiety.\textsuperscript{41,43,48} Although a randomized, controlled study comparing paroxetine and nortriptyline showed superiority of nortriptyline in alleviating anxiety and depression,\textsuperscript{43} another randomized, controlled study comparing desipramine and citalopram found improvement with both treatments.\textsuperscript{48} A placebo-controlled study reported a suggestion of effectiveness of atomoxetine in PD.\textsuperscript{49} These findings support a role for both serotonergic and noradrenergic system in the neurobiology of anxiety in PD.

**Anatomical and Metabolic Correlates**

Many anatomical changes in the brain have been observed in PD-associated depression. The temporal cortex, particularly the amygdala and hippocampus, is atrophic, and this could explain mood/emotion learning deficits.\textsuperscript{51-56} The role of the orbitofrontal cortex (OFC) has also been highlighted by MRI studies that showed atrophy of this region correlating with severity of depression in PD.\textsuperscript{52,53,57} Furthermore, \textsuperscript{18}F-FDG and H\textsubscript{2}\textsuperscript{15}O PET studies have revealed hypometabolism of the OFC in both depressed and “simply dysphoric” PD patients.\textsuperscript{58,59} However, the pattern of abnormalities of OFC activity remains the subject of debate. Some fMRI studies have yielded results to the contrary, with increased resting-state activity of the OFC. This could be interpreted as an abnormally increased top-down control over limbic circuits, leading to abnormal avoidance behavior.\textsuperscript{60}

Depression scores in PD are predicted by the variations in the amplitude of low-frequency fluctuations measured by MRI at rest in the dorsolateral prefrontal cortex (DLPFC) and ventromedial prefrontal cortex (vmPFC). This is interesting in relation to the role of DLPFC in executive functions and response selection and to the role of the vmPFC in providing the contextual value of reward, emotion, and perception processing.\textsuperscript{61}

Finally, atrophy of the dorsal anterior cingulate cortex (ACC), which plays an important role in motivation, conflict monitoring, response initiation, social behaviors, and reward encoding, has also been found in depressed PD patients.\textsuperscript{51,55,57,62} This could participate in the reduction of initiative and motivation to initiate actions observed in depressed PD subjects. The ventral part of the ACC also plays a prominent role in the pathophysiology of depression in PD, and a relationship between its activity and metabolism and depression severity has been noted.\textsuperscript{54,60,63,64}

Amygdala dysfunction also plays a role in the pathophysiology of depression in PD, with increased activity and reduced connectivity with frontoparietal areas.\textsuperscript{65} Finally, subcortical regions are also involved in PD depression, in particular, the limbic part of the thalamus, which has been found to be atrophic and hypoactive during emotional perception.\textsuperscript{66,67}

More recently, a number of MRI connectivity studies have revealed widespread reduction of connectivity in cortico-subcortical limbic circuits and increased connectivity between certain specific limbic areas such as the amygdala, limbic thalamus, and temporal cortex in depressed PD subjects. This indicates that depression in PD is linked not only to focal abnormalities, but also to global dysfunction in interaction between areas.\textsuperscript{60,68,69} Some authors point out a possible increase in connectivity between limbic regions and a decrease in connectivity in corticolumbic networks, which may reflect abnormal top-down control on emotion-related limbic regions.\textsuperscript{59}

**Neurotransmitter Abnormalities**

**Role of Dopaminergic Lesions**

Degeneration of mesocorticolimbic dopaminergic projections to the ACC, OFC, ventral striatum, and thalamus appears to be one of the key mechanisms responsible for depression in PD. This has been demonstrated by several SPECT or PET studies using the dopamine D\textsubscript{2} receptor antagonist [\textsuperscript{11}C]-raclopride,\textsuperscript{70} [\textsuperscript{18}F]-dopa,\textsuperscript{71,72} dopamine transporter (DAT) ligands [\textsuperscript{99mTc}]Tc-TRODAT-1\textsuperscript{73} or [\textsuperscript{11}C]RT132 a ligand to both DAT and noradrenalin transporter.\textsuperscript{74} However, DAT imaging studies have sometimes yielded conflicting results. Indeed, some have revealed a reduction in DAT binding in depressed PD patients, which is an argument in favor of greater dopaminergic degeneration. However, other studies have found quite the opposite and suggest that abnormally high dopamine clearance results in reduced dopamine tonus.\textsuperscript{76,77} Clarification is necessary, but overall, involvement of the dopaminergic system in depression associated with PD is a clear-cut finding. In particular, the involvement of the mesolimbic dopaminergic pathway was neatly highlighted by a combined PET [\textsuperscript{11}C]-PHNO (a predominant D3-receptor ligand) and [\textsuperscript{11}C]-raclopride (a mixed D2/D3 receptor ligand) study showing an association between lower mood and a greater dopamine D3 versus dopamine D2 receptor alteration in PD.\textsuperscript{79} Involvement of the dopaminergic system has also been demonstrated in anxiety, indicating the existence of a common mechanism.\textsuperscript{70,73,74}

**Role of Serotonergic Lesions**

The serotonergic system is altered in PD, notably in limbic areas such as the medial temporal cortex and frontal regions, and in the raphe and hippocampus independently of the presence of depression as shown by PET imaging studies using [\textsuperscript{11}C]WAY100635, a 5-HT\textsubscript{1A} receptor antagonist\textsuperscript{80,81} or [\textsuperscript{11}C]-FP-CIT.\textsuperscript{82} PET studies using [\textsuperscript{11}C]-DASB, a serotonin transporter
ligand, in PD patients who are depressed have shown increased binding of the transporter, which could suggest excessive reuptake of serotonin.\(^{83,84}\) Furthermore, decreased postsynaptic serotonin 1A receptor density within limbic territories has been demonstrated using PET and \(^{18}F\)MPPF, a selective serotonin 1A receptor antagonist, in depressed PD patients.\(^{85}\) This supports the role of serotonergic system dysfunction in the pathophysiology of depression in PD and fits well with neuropathological data.\(^{86}\) Further evidence has come from the observation, in grafted PD patients, that after the restoration of dopaminergic innervation, the persistence of depressive manifestations were related to greater serotonergic lesions.\(^{87}\) This remains the subject of debate and a large and recent \(^{123}I\)-FP-CIT SPECT study found no association between serotonergic lesions in the raphe nucleus and depression score in early-stage PD patients.\(^{82}\) However, these last results should be interpreted carefully, as this study only analyzed correlations between depression score and \(^{123}I\)-FP-CIT binding and did not include patients with clinically defined depression. This may suggest that the involvement of the serotonergic system in the pathophysiology of depression in PD could be different according to the stage of the disease and more prominent when disease progresses.

**Role of Noradrenergic Lesions**

Only 1 PET imaging study has reported a link between the presence of depression and the degree of noradrenergic lesions in the locus coeruleus and limbic areas such as the anterior cingulate cortex, amygdala, and ventral striatum.\(^{75}\) However, it has to be acknowledged that the tracer used in this study (\(^{11}C\)-RTI-32) is a marker of both dopamine and noradrenergic system.\(^{88}\)

**Animal Studies**

Lesion-based rodent models have recently afforded interesting insight into the pathophysiology of depression and anxiety in PD.\(^{88-90}\) Several studies have used bilateral and partial dopaminergic lesions of the nigrostriatal system (Fig. 1) to avoid causing motor impairment so severe that it would preclude any nonmotor behavioral evaluation. Such bilateral and partial dopaminergic lesions induced anxiety- and depression-related behaviors in lesioned rats.\(^{88-90}\) Very recently, a depression-like phenotype was also observed in an α-synuclein-based rodent model.\(^{91}\) Interestingly, these behavioral deficits are corrected by dopaminergic medication, notably D2/D3 receptor agonists such as pramipexole.\(^{88,89}\) This confirms the role of dopamine dysfunction in PD-related affective disorders and highlights the predictive value of such rodent models in the study of nonmotor, behavioral PD symptoms. In contrast to human functional imaging studies, these preclinical data rather point toward involvement of the nigrostriatal dopaminergic system.\(^{73}\) However, regarding the relative anatomofunctional organization of the ascending dopamine pathways,\(^{92}\) further investigation is needed to determine their exact contribution to the development of depression in PD. Some animal-based research data suggest that, in addition to the

---

**FIG. 1.** Bilateral and partial substantia nigra pars compacta (SNc) dopaminergic lesions induce motivational deficits that are reversed by pramipexole. (A) Stereotaxic infusion of 6-OHDA leads to a loss of dopaminergic innervation in the dorsal striatum, mainly in its lateral part. Representative photomicrographs of coronal sections stained for tyrosine hydroxylase (TH) in striatal (1.7 to 0.7 mm anterior to bregma) and mesencephalic (-5 to -5.8 mm anterior to bregma) regions according to the stereotaxic atlas of Paxinos and Watson, 1998. Bar = 1 mm. The intensity of the gradient of color (white to blue) in schematic sections corresponds to the measured dopaminergic lesioned area. The highest intensity of blue color (100%) indicates that all animals had lesions in the corresponding area, whereas the lowest color intensity (white, 0%) corresponds to a nonlesioned or denervated area. (B) SNc dopaminergic lesions, which do not induce bradykinesia, greatly reduce operant sucrose self-administration (postlesion phase), a deficit corrected by chronic administration of low doses of pramipexole 0.2 mg/kg intraperitoneally (treatment phase). This beneficial effect of pramipexole disappears when the treatment is interrupted (withdrawal phase). Data are represented as mean number of sucrose deliveries ± SEM. Data for each phase were sampled from the last 6 operant sessions. Adapted from Drui et al, 2014, and Favier et al, 2014. PRA, pramipexole.
Apathy and Fatigue

Clinical Findings

Apathy is one of the most common and disabling neuropsychiatric symptoms in PD. It can be defined as lack of motivation, resulting in decreased goal-directed behaviors, and variably decreased interests and emotions. An emotional and a cognitive dimension can be recognized in apathy. Its prevalence in PD ranges from 15% to 70% depending on disease severity and on the diagnostic tool used. Apathy can present in isolation or in association with depressed mood or cognitive decline. It is one of the most frequent symptoms in untreated de novo PD. One case-control study has shown that it can precede disease onset. Several studies in early PD have shown that apathy correlates with more severe motor impairment, suggesting an underlying common mechanism such as dopaminergic denervation.

Apathy has been reported to improve with levodopa and dopamine agonists in treated PD patients and with the MAO inhibitor rasagiline in early untreated PD. More evidence of the dopaminergic nature of apathy comes from experience with patients operated on with STN DBS. A recent study used experimental pharmacological management, reducing levodopa therapy as much as possible and completely stopping dopamine agonists after surgery. Half the patients on STN DBS managed with such drastic withdrawal of dopaminergic treatment developed apathy during the first year after surgery. Half the apathetic patients also developed depression. Apathy in this population was improved by treatment with piribedil, a D2-D3 dopamine agonist, in a randomized placebo-controlled trial. Although postoperative apathy had been attributed to STN DBS by itself in the literature, the authors took the reversibility of apathy after reintroduction of a dopamine agonist as proof that postoperative apathy in patients with STN DBS is indeed related to withdrawal of dopaminergic treatment in the same way that dopamine agonist withdrawal syndrome has been described in parallel in patients with rapid decrease in dopamine agonists. In a randomized study comparing subthalamic stimulation with best medical treatment, avoiding marked postoperative reduction of dopaminergic medication, no difference in apathy was found between the 2 groups. This provides further support for the idea that postoperative apathy can be managed by optimal drug management and is the consequence of excessive withdrawal of dopaminergic treatment and not of stimulation per se. It should be noted that it is important to detect and treat the appearance of postoperative apathy as it can nullify the benefits of motor improvement for quality of life (QOL).

Although apathy responds to dopaminergic treatment, there are no systematic studies showing improvement of apathy with antidepressant treatment. Single case reports, however, have described good response of apathy to dopaminergic treatment after ineffective trials with serotonergic and noradrenergic antidepressant treatment, pointing to a major role of dopamine as the key neurotransmitter in motivational deficit.

In a double-blind, placebo-controlled study in PD patients with moderate to severe apathy without dementia and depression, significant improvement of apathy was reported following treatment with rivastigmine, suggesting that cholinergic denervation may also participate in parkinsonian apathy.

In advanced PD, apathy may be associated with dementia. The diffuse cortical synucleinopathy of advanced PD corresponding to Braak stages IV and V can by itself explain apathy. In this case it is no longer possible to reverse apathy by dopaminergic replacement therapies. The management of apathy with dopaminergic drugs therefore should also take into account the presence or absence of cognitive deterioration.

Interestingly, it was recently shown that in de novo PD, after adjustment for confounding factors such as cognitive impairment or motor severity, apathy correlated strongly with fatigue and anhedonia, which is impaired ability to experience pleasure. Fatigue is one of the most common premotor symptoms in PD. The association between apathy and fatigue has also been observed in PD patients undergoing treatment. The neurobiological bases of fatigue are still unclear, and its management remains unsatisfactory. A subjective complaint of fatigue may express different underlying disorders such as somnolence, motor fatigability, or lack of motivation. Several studies have suggested...
improvement in fatigue with dopamine agonists,\textsuperscript{18,35,36,113} levodopa,\textsuperscript{114} and the MAO inhibitor rasagiline.\textsuperscript{32} Analysis of neuropsychiatric signs in the Parkinson’s Progressive Markers Initiative, a prospective longitudinal study following early untreated PD patients and healthy controls, revealed improvement in fatigue with dopaminergic treatment.\textsuperscript{26} However, most available data come from studies that did not assess fatigue as a primary end point and that did not use fatigue scales. Interestingly, a recent pilot double-blind, placebo-controlled study specifically designed to assess fatigue found improvement of fatigue in the rasagiline group compared with the placebo group, supporting implication of the dopaminergic system.\textsuperscript{115} Further studies are needed to confirm this role. The association of apathy and fatigue deserves further investigation. In our experience most apathetic patients do not have spontaneous complaints besides fatigue.\textsuperscript{18} Apathy can easily remain undetected during neurological evaluation, unless specifically screened for. In our view, the association between apathy and fatigue therefore might be particularly interesting, as fatigue could represent a “red flag” for apathy.

**Anatomical and Metabolic Correlates**

MRI studies involving apathetic PD patients have shown atrophy of the precuneus, possibly responsible for a lack of insight about the inferior parietal and frontal gyrus and possibly involved in difficulties in integrating information in attention deficit and in dys-executive syndrome and of the insula, which could lead to a loss of emotional responsiveness.\textsuperscript{52}

Abnormal increased activity of the OFC has also been found using PET \textsuperscript{[18]F}-FDG or resting-state fMRI.\textsuperscript{54,116-118} This could explain excessive top-down OFC control of limbic circuits and, in turn, abnormal avoidance behavior. In addition, the degree of apathy correlates with variations in amplitude of low-frequency fluctuations of the OFC, again pointing to the key role played by this area.\textsuperscript{54}

Although apathy in PD is associated with dorsal ACC atrophy, metabolism in this area is increased, possibly to compensate.\textsuperscript{51,52,54,55,62,116,118} ACC dysfunction appears to be crucial in any explanation of the cognitive and emotional aspects of apathy because of the role this area plays in emotional self-control, problem solving, error recognition, and adaptive response to changing conditions.

The SMA is also involved. SMA activity is diminished in apathetic PD patients and predicts the severity of apathy. Because of the SMA’s role in motor programming and execution of intended action sequences, this could explain the lack of motivation.\textsuperscript{54}

Subcortical regions are also involved in apathy, in particular, the nucleus accumbens, which has been shown to be atrophic and abnormally shaped in apathetic subjects.\textsuperscript{119} Another recent study found that hypometabolism of the ventral striatum is associated with the risk of becoming apathetic after STN stimulation in PD, pointing, again, to the importance of this region, which plays a major role in reward processes.\textsuperscript{120}

More recently, apathetic PD patients were seen to have reduced functional connectivity between areas of cortico-subcortical limbic circuitry,\textsuperscript{121} stressing the presence of global dysfunction across a large network. Detailed analysis of the existing literature on apathy related to brain lesions has shown that different neural networks subserve emotional-affective, cognitive, and autoactivation aspects of apathy.\textsuperscript{96}

**Neurotransmission Abnormalities**

Thanks to PET imaging studies using \textsuperscript{[11]C]-raclopride, the role of dopaminergic denervation now appears very clearly as a key factor in explaining the development of apathy in PD. The presence of more diffuse and more severe dopaminergic denervation in mesocorticolimbic circuits in PD patients is associated with greater risk of developing apathy after STN stimulation.\textsuperscript{70} Another PET study using \textsuperscript{[11]C]-RTI32, a ligand for both DAT and the noradrenalin transporter, also revealed the involvement of limbic dopaminergic but also noradrenergic lesions in apathy and in depression and anxiety.\textsuperscript{75} The role of dopaminergic denervation in the occurrence of apathy was also demonstrated using several dopaminergic PET tracers in MPTP monkey models.\textsuperscript{122,123} Recently, in de novo drug-naive PD patients exhibiting apathy, greater dopaminergic denervation was found in the right caudate nucleus.\textsuperscript{124}
suggesting that dopaminergic denervation is linked to apathy regardless of disease stage. Moreover, recent and unpublished findings of our group suggest that combined dopaminergic and serotonergic degeneration, especially within the basal ganglia network, could be a key mechanism underlying apathy in de novo PD patients. Therefore, such results suggest that the pathogenesis of this symptom is complex and is not exclusively linked to dopaminergic disruption (Fig. 2).125

Animal Studies

Although there are fewer studies than on depression and anxiety, preclinical studies also support the involvement of dopamine in the pathophysiology of apathy and anhedonia.73 As mentioned previously,122,123 diffuse DA lesions in MPTP monkey models lead to a reduction in goal-directed behavior and behavioral activities that resembles apathy (see also reference 126). In addition, partial and bilateral DA lesions of the nigrostriatal system of rats induce strong motivational deficits that can be reversed by DA agonists89,127,128 (Fig. 1). Bilateral loss of dopaminergic denervation can also lead to anhedonia-like behavior in mice and rats.88-90 Again, these studies do not make it clear whether apathy intrinsically results from the loss of dopamine in the nigrostriatal system or from the diffusion to the ventral tegmental area.

Hypodopaminergic Behavioral Syndrome

Depression, anxiety, and apathy can be defined as a hypodopaminergic syndrome that can precede motor onset and develop over the course of the disease (Fig. 3).

They may be associated with other nonmotor symptoms such as fatigue.

Apathy occurring during premotor PD can account for the typical premorbid parkinsonian personality128,130 of reduced sensation seeking, reduced smoking, and lower alcohol and caffeine intake. Apathy can be seen as the nonmotor emotional counterpart of akinesia. The neurobiological basis of depression and anxiety seems more complex than the purely dopaminergic basis. Dopaminergic sensitization in the motor loop induces the development of dyskinesia. In the same way, sensitization of the limbic and cognitive loops explains the switch from hypodopaminergic symptoms to a hyperdopaminergic behavioral syndrome (behavioral and dopaminergic replacement treatment addiction, nocturnal hyperactivity, hypomania, and punding)5,6,8 (Video), as well as changes in the personality traits of PD patients. In the early levodopa era, Oliver Sacks had already described a shift induced by dopaminergic medication from apathy to an opposite behavioral state that he proposed to call a “hyperpathy” to summarize what today would rather be defined as hyperdopaminergic behaviours (Fig. 4).131
The severity of the clinical hypodopaminergic syndrome, which reflects the extent of the dopaminergic lesion, seems to be the main risk factor for developing hyperdopaminergic behavioral complications and nonmotor psychic fluctuations while on dopaminergic treatment.7,70,132 The pulsatility of dopaminergic treatment, selective D3-receptor stimulation, and duration of treatment are the main risk factors of pharmacological management to develop such behavioral complications (Fig. 3).7,132-136

In conclusion, apathy, anxiety, depression, and fatigue can all be classified under the umbrella of hypodopaminergic syndrome. This is a pragmatic oversimplification, as dopamine is the main, but not the only, neurotransmitter involved. The concept of hypodopaminergia is useful, though, in the clinical management of PD patients, as all these symptoms can be improved with dopaminergic medication. It is important to detect the symptoms of hypodopaminergia, as they have a major impact on QOL.29,108 Symptoms can be improved with a positive effect on patients’ QOL. However, their presence requires careful treatment strategies because hypodopaminergic symptoms might represent a risk factor for developing impulse control disorders, behavioral addictions, and dopamine dysregulation syndrome.7 In our view, this strategy should not be applied only after sensitization has taken place and the patient has already developed pathological hyperdopaminergic behavioral disorder, but should be started early on, as soon as patients start developing changes in behavior with hyperdopaminergic symptoms that do not correspond to psychiatric disease, to prevent excessive sensitization and severe pathology. Possible strategies should rely on highly fractionated low doses of L-dopa, associated with MAO-I and COMT-I, which have longer-lasting effects than L-dopa in isolation individually adapted doses of D3 receptor agonists not exceeding the threshold for clinical signs of hyperdopaminergic behavior and combination with nondopaminergic or with dopamine-sparring drugs whenever useful.7 ●

Acknowledgments: The work shown in Figure 1 was supported by the Institut National de la Santé et de la Recherche, Fondation Neurosciences et Association France Parkinson. The work shown in Figure 2 was supported by the Agence Nationale de la Recherche, the Fondation pour la Recherche Médicale, the France Parkinson Association, the Federation Française pour le Groupement des Parkinsoniens, and UCB Pharma, as well as the Hospices Civils de Lyon.

References


Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.